M
NYMX

Murchinson’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Murchinson’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-76,404
Closed -$96K – 129
2022
Q1 		$96K Buy
+76,404
New +$118K 0.02% 81

Other funds holding NYMX

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
WB
Webster Bank Waterbury, Connecticut $1.15B AUM 23.08% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
WP
WMS Partners Towson, Maryland $1.78B AUM 11.82% 1-Year Est. Return
FCFC
First Citizens Financial Corp Mason City, Iowa $239M AUM 26.56% 1-Year Est. Return

Murchinson's NYMX Position: Q2 2022 in Review

Murchinson sold out of Nymox Pharmaceutical Corp (NYMX) in Q2 2022, closing a stake of 76,404 shares — an estimated $96K sold.

Murchinson first reported a position in NYMX in Q1 2022 and held it in 1 quarter. The position peaked at $96K in Q1 2022. 39 funds tracked by Wall St. Rank hold NYMX as of Q2 2022.

  • Murchinson reported no remaining Nymox Pharmaceutical Corp position as of Q2 2022 after selling out during the quarter.
  • Murchinson sold 76,404 Nymox Pharmaceutical Corp shares in Q2 2022, an estimated $96K.
  • Murchinson first reported a position in Nymox Pharmaceutical Corp in Q1 2022 and held it in 1 quarter.
  • Murchinson's Nymox Pharmaceutical Corp position peaked at $96K in Q1 2022.
  • 39 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q2 2022.

Based on Murchinson's 13F filing for Q2 2022, filed 15 Aug 2022.